Edward Dyson

Ed counsels public and emerging private companies, entrepreneurs, investors and investment banks on a wide range of capital markets and corporate finance transactions.

• Engagements

  IPOs / Direct Listings / Follow-ons:

  • Ananda Pharma plc on its US OTCQB listing
  • RegTech Open Project plc on its Main Market direct listing
  • Kistos Holdings plc on its AIM direct listing
  • Zamaz plc on its Main Market direct listing and PIPE
  • OKYO Pharma Limited on its Main Market IPO, Nasdaq dual-listing, Main Market de-listing and global follow-ons
  • Panther Metals plc on Main Market follow-ons
  • Supply@ME Capital plc on Main Market follow-ons
  • Codex Acquisitions plc on its Main Market IPO
  • URA Holdings plc on its Main Market IPO
  • Hamak Gold Limited on its Main Market IPO
  • VEF AB on its First North to Nasdaq Stockholm Main Market listing step-up
  • Tiziana Life Sciences Limited on its AIM to Main Market listing step-up, Nasdaq dual-listing, Main Market de-listing and redomiciliation
  • Attica Bank S.A. on various Athens Stock Exchange follow-ons
  • e-Therapeutics plc on its US OTCQX listing
  • Mercantile Ports & Logistics Limited on AIM follow-ons
  • AccuStem Sciences Inc. on its demerger and US OTC listing
  • Farmacosmo S.p.A. on its Euronext Growth Milan IPO
  • the financial advisers on a convertible loan note financing by Hawkwing plc
  • Heptares Therapeutics Limited on the Nasdaq IPO of Centessa Pharmaceuticals plc
  • Hummingbird Ventures on the Main Market IPO of Deliveroo plc
  • the financial adviser on a placing by Nuformix plc
  • National World plc on its Main Market IPO
  • Endava plc on its NYSE IPO
  • Renalytix plc on its demerger, AIM IPO and Nasdaq dual-listing
  • the underwriters on the Nasdaq IPOs of Compass Pathways plc, Horizon Discovery plc (aborted), Bicycle Therapeutics plc, Kymab Limited (aborted) and Mereo BioPharma Group plc (aborted)
  • Autolus Therapeutics plc on its Nasdaq IPO
  • Nightstar Therapeutics plc on its Nasdaq IPO
  • Scancell Holdings plc on various AIM follow-ons
  • Realm Therapeutics plc on its direct dual-listing on Nasdaq and subsequent AIM delisting
  • B&M European Value Retail S.A. (B&M Stores), TCS Group Holdings plc (Tinkoff), "Romgaz" S.A., on their Main Market IPOs
  • the underwriters on the Main Market IPOs of Exova Group plc and Glencore plc
  • the financial advisers on the Main Market introduction of Metro Bank plc

  Public / Private M&A:

  • National World plc in connection with its final* recommended cash acquisition by Media Concierge (Holdings) Limited
  • National World plc in connection with the auction of The Telegraph Media Group
  • Nxera Pharma on its acquisition of Idorsia’s Japan and APAC (ex-China) pharmaceuticals business
  • Kistos Holdings plc on its acquisition of Mime Petroleum A.S.
  • National World plc on its possible offer for Reach plc
  • Kistos plc on its possible offer for Serica Energy plc
  • Pires Investments (now Mindflair) plc on its proposed takeover by Tern plc
  • Realm Therapeutics plc on its recommended takeover by Essa Pharma Inc.
  • MightyHive Inc. on its acquisition by S4 Capital plc

  De-SPACs / Reverse Takeovers:

  • Technologies New Energy plc on its Main Market de-SPAC of Technologies New Energy S.A.
  • Atlas Metals Group plc on its (aborted) Main Market reverse takeover of Compagnie Minière de Oumejrane 
  • Kistos plc on its reverse takeover of Tulip
  • National World plc on its reverse takeover of JPI Media
  • VNV Global AB on the Nasdaq de-SPACs of Swvl with Queen's Gambit Growth Capital and Gett with Rosecliff Acquisition Corp I
  • Kinnevik AB on the NYSE de-SPAC of Babylon Health with Alkuri Global Acquisition Corp.
  • RockRose Energy plc on its reverse takeovers of certain North Sea interests acquired from Marathon Oil and Idemitsu Petroleum

  Private Capital:

  • A financial investor on a Seed financing round for a UK fintech
  • A tech business on its Series A financing
  • FOMTECH Limited (Floww) on its Series B and C financings
  • Metro Africa Xpress Inc. on its Series B financing

  Strategic Advisory:

  • capAI plc on corporate matters
  • Floww on its strategic partnership with London Stock Exchange Group to create a global private capital market
  • Force Over Mass Capital LLP on partnership matters
  • Round Group Limited on the establishment of its Apex influencer and creator business
  • Nxera Pharma on its collaboration and licensing agreements with Neurocrine Biosciences Inc., Eli Lilly and Co., Viatris and another global biomedical company

  Please note: Ed's experience includes that prior to joining Orrick.